Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
7 evidence topics · 10 sources
Summary
- Treatment goals: disease-modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and extending lifespan beyond that predicted by natural history data. Treatment goals are established at diagnosis and reviewed regularly, aiming to improve or maintain physical and psychosocial wellbeing.
- Survival in the label analysis: the FDA examined the survival of 36 participants treated with Lembaz across three clinical studies and an expanded access program against a matched external control group. Deaths occurred in 12 (33.3%) LEMBAZ-treated participants and 24 (66.9%) controls; the hazard ratio for death was 0.45 (95% CI 0.21, 0.95), a 55% reduction in the risk of death, and median survival was 8.5 years with treatment and 4.9 years in controls. Longer overall survival was observed independent of baseline miglustat use.
- Survival in a separate company analysis: deaths occurred in 17 (23.6%) adrabetadex-treated participants and 44 (61.2%) external controls, with a hazard ratio of 0.289 (95% CI 0.141, 0.593; P < 0.0001), reported by the company as a 71% reduction in the risk of mortality; the 5-year survival rate was 84% with adrabetadex and 42% in external controls.
- Disease progression: in a company analysis of 79 treated participants, the annual rate of progression on the rescored 4-domain NPCCSS fell from 1.34 units/year before treatment to 0.76 units per year after treatment, a 43% reduction (P=0.0055). An observational cohort receiving routine clinical care progressed by 1.5 units/year on the 5-domain NPCCSS. The company approval announcement states: “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”. Among five individuals treated with intrathecal HPBCD for 4 to 11 years, some disease progression continued.
- Expected harm: treatment with LEMBAZ has resulted in permanent hearing impairment; 37% (22/59) of patients in Trial 3 and an expanded access program experienced hearing impairment.
Guideline definition of disease-modifying therapy
“For the purpose of this paper, disease‐modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and ultimately extending lifespan beyond that predicted by available natural history data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To understand the effects of disease‐modifying therapy in NPC, information about the natural history of disease progression is required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline treatment goals and follow-up
“Statement #19: NPC is a progressive condition, and patients require regular follow‐up to monitor disease severity, treatment response, and recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment goals should be established at diagnosis and reviewed regularly, aimed at improving or maintaining the physical and psychosocial wellbeing of individuals with NPC and their families.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote